Almond vs Whey Protein Drinks: Similar Acute Effects on Appetite, GI Symptoms and Hydration in Postmenopausal Women
بروتين اللوز مقابل مصل الحليب: تأثيرات حادة متشابهة على الشهية والأعراض المعوية والترطيب لدى النساء بعد انقطاع الطمث
Journal: Frontiers in nutrition
University: Not reported
Study Type: RCT
Evidence Level: preliminary
Participants: 9
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
In a randomized crossover trial of nine postmenopausal women, single-dose almond protein and whey protein beverages (29.5 g protein each) produced comparable acute effects on appetite, gastrointestinal symptoms and hydration versus placebo and water. The small sample size and single-dose design make the results preliminary and not broadly generalisable.
1-Minute Summary
This randomized crossover RCT tested acute responses to almond protein powder (APP), whey protein (WP), placebo and water in nine postmenopausal women (mean age 60±4 y). Appetite ratings, gastrointestinal symptoms (GIS) and hydration measures were assessed after each treatment. Results indicated APP and WP elicited comparable short-term effects on appetite regulation, GIS and hydration. Because the study used a small sample and single-dose acute assessments, findings are preliminary and require confirmation in larger, longer trials.
3-Minute Summary
Background and objective: The study examined acute effects of an almond-derived protein powder (APP) versus a matched dose of whey protein (WP) on appetite regulation, gastrointestinal symptoms (GIS) and hydration in postmenopausal women — a population with age- and menopause-related shifts in appetite signalling, gastrointestinal function and body water regulation. Because APP delivers protein together with residual fibre and unsaturated fat (a by-product of oil extraction), it could plausibly produce a different short-term physiological and perceptual response than WP. The authors ran a randomized crossover trial in nine postmenopausal women (mean age 60 ± 4 y) comparing four single-dose treatments: APP (29.5 g protein), WP (29.5 g protein), a placebo, and water. Design and outcomes: The crossover design means each participant received all four treatments on separate visits, reducing between-subject variability. Primary outcomes reported were subjective appetite (likely measured by validated visual analogue scales), GIS, and measures of hydration (the abstract does not list specifics). The trial tested acute post-ingestion responses over a measured time course. Key finding: According to the article title and abstract, APP and WP elicited comparable appetite regulation, GIS and hydration responses in this sample. In other words, despite compositional differences (APP containing fibre and unsaturated fat in addition to protein), the acute subjective and hydration responses did not differ meaningfully between the plant-based APP and animal-derived WP. Interpretation and probable mechanisms: Several mechanisms could explain the finding. Protein is a potent acute suppressor of appetite relative to carbohydrate or fat; when protein dose is matched (29.5 g in both treatments), dominant satiety signalling may be similar across proteins. If APP contained modest amounts of fibre and fat, those components could slow gastric emptying or affect gut-derived peptides (e.g., GLP-1, PYY), but either the amount was insufficient to change subjective appetite in an acute setting, or homeostatic and hedonic appetite drivers converged to produce comparable ratings. Hydration equivalence may reflect similar beverage volume and osmolarity or rapid compensatory renal handling that equalized measures over the observation period. GIS similarity suggests neither protein source produced substantially greater acute gastrointestinal intolerance in this cohort. Clinical and research framing: The results are preliminary and specific to an acute, single-dose setting in a small, homogeneous sample of postmenopausal women. They speak to short-term tolerability and subjective appetite but cannot be extrapolated to chronic effects on body weight, long-term hydration status, nutrient absorption, metabolic health, or disease outcomes. Concluding takeaway: In this small randomized crossover trial, matched doses of almond-derived protein powder and whey protein produced similar short-term subjective appetite ratings, gastrointestinal symptom profiles and hydration responses in postmenopausal women. The finding supports the notion that a plant-derived almond protein product may be an acceptable acute alternative to whey in terms of these immediate outcomes, but larger and longer-duration studies with objective physiological measures are needed before broader conclusions can be drawn.
Full Analysis
Context and rationale Postmenopausal women undergo endocrine and body-composition changes (e.g., reductions in estrogen, redistribution of fat mass, altered lean mass, and possible changes in thirst and renal handling) that can influence appetite regulation, gastrointestinal function and hydration. Protein supplements are widely used for appetite control, muscle maintenance and as convenient nutrition sources. Almond protein powder (APP), produced after oil extraction from almonds, contains protein but also residual fibre and unsaturated fats; these co-nutrients could modulate gastric emptying, gut peptide release, microbiome interactions and subjective tolerability differently from a purified dairy protein such as whey. Testing APP against WP in a controlled acute setting addresses an evidence gap about plant-based protein alternatives tailored to an older female population. Study design and internal validity The authors used a randomized crossover design in nine postmenopausal women (mean age 60 ± 4 y). Each participant received four treatments (APP 29.5 g protein, WP 29.5 g protein, placebo, and water) across different visits. Crossover designs are efficient for small samples because each participant serves as her own control, reducing between-person variability. Randomization of treatment order alleviates sequence effects; however, crucial details that determine internal validity include adequacy of washout periods (to prevent carryover), blinding procedures (participants and assessors), and whether beverage appearance, texture and energy content were matched beyond protein content. The abstract does not provide these details; if blinding was imperfect (taste differences often exist between almond-based and whey-based beverages), expectancy effects could influence subjective appetite/GIS ratings. Outcome measurement considerations The study reports outcomes for appetite, GIS and hydration. Standard practice in appetite research is to use validated visual analogue scales (VAS) for subjective hunger, fullness, prospective food intake and desire to eat. GIS are typically assessed with Likert scales for nausea, bloating, cramping, flatulence and related symptoms. Hydration measures can be subjective (thirst ratings) and objective (body mass changes, urine volume/osmolality, plasma osmolality, electrolyte concentrations). The abstract truncation prevents confirmation of which objective markers were used. For robust interpretation, objective hydration markers should complement subjective reports because compensatory renal and vascular responses can mask transient fluid shifts. Principal findings and plausible biological interpretation The principal claim—that APP and WP elicited comparable appetite regulation, GIS and hydration responses—suggests that when protein dose is matched (29.5 g), the acute satiety and tolerability effects converge across these protein sources in this population. Protein’s capacity to suppress hunger and increase fullness is well-established; matching grams of protein likely standardised the dominant satietogenic signal. Additional components in APP (fibre, unsaturated fat) might have been expected to enhance satiety or slow gastric emptying; however, either their quantities were too small to detect an acute effect, or the study’s statistical power was insufficient to detect small-to-moderate differences. Similarly, hydration responses depend on beverage volume, sodium/osmolarity and renal handling; matched volumes and rapid homeostatic responses can produce similar net hydration indices in the short term. Statistical and sample-size limitations Nine participants is typical for preliminary mechanistic crossover studies but limits statistical power and generalisability. Small N increases the risk of Type II error (failing to detect a real difference) and magnifies the influence of individual outliers. The abstract does not present effect sizes, confidence intervals or p-values; without these, it is impossible to judge whether the reported ‘comparable’ outcome reflects true equivalence (statistical equivalence testing) or nondifference due to low power. For claims of comparability, equivalence or noninferiority testing (with predefined margins) would be preferable to simple null-hypothesis testing. Generalisability and external validity The cohort—older postmenopausal women—represents a clinically relevant group but is small and probably homogeneous in other respects (ethnicity, health status, habitual diet). Findings may not generalize to men, younger women, people with obesity or metabolic disease, or habitual consumers of high-fibre diets. Acute single-dose responses do not predict chronic outcomes like weight regulation, lean mass preservation, metabolic markers, or long-term gastrointestinal adaptation. Methodological gaps and reporting limitations Because the provided abstract is truncated, key methodological elements are unclear: exact appetite and GIS instruments, timing and frequency of measurements, hydration markers, washout duration, randomization sequence, blinding, beverage energy and macronutrient matching beyond protein, and statistical approach (e.g., mixed models accounting for period effects). Absence of reported effect sizes, variance measures and p-values in the provided text prevents quantitative appraisal. Missing biochemical measures (gut peptides, gastric emptying tests, blood osmolality) limits mechanistic inference. Practical implications and future directions The study offers initial evidence that APP may be comparable to WP for immediate subjective appetite responses and tolerability in postmenopausal women at an acute matched-protein dose. Future studies should: (1) enlarge sample size and include power calculations to detect clinically meaningful differences; (2) extend to repeated dosing or longer-term interventions to evaluate sustained appetite regulation, energy intake and body-composition outcomes; (3) include objective physiological measures (gastric emptying, GLP-1/PYY/ghrelin, urine/plasma osmolality, electrolytes); (4) ensure blinding and sensory matching of test beverages; (5) test equivalence/noninferiority with predefined margins; and (6) examine subgroups (e.g., women with obesity, renal impairment, or nut allergies). Ethical and safety considerations All nutritional interventions should monitor allergy risk (nuts), renal function (if high-protein regimens are considered chronically) and gastrointestinal tolerability. Reporting adverse events and dropout reasons is essential for assessing real-world acceptability. Summary judgement This randomized crossover trial offers an informative, hypothesis-generating signal that an almond-derived protein powder can match whey protein on acute subjective appetite, GIS and hydration responses in a small sample of postmenopausal women. However, limitations—most notably small sample size, limited methodological detail in the available abstract, lack of objective mechanistic markers and short-term assessment—mean conclusions should be cautious. Larger, well-powered, methodologically transparent trials are needed to determine whether plant-based almond protein is a robust alternative to whey for appetite control, tolerability and hydration in this population.Health Implications
Practical implications should be cautious. This trial’s acute results suggest that, for single-serving intake, an almond-derived protein powder providing ~29.5 g protein produced similar short-term appetite, gastrointestinal tolerability and hydration responses as an equal dose of whey protein in a small group of postmenopausal women. For day-to-day practice this implies APP could be a tolerable plant-based alternative to whey for immediate satiety and short-term tolerance in similar individuals, particularly for those preferring plant proteins or avoiding dairy. However, because the evidence is preliminary and limited to single-dose responses, individuals and clinicians should avoid assuming long-term equivalence for weight, metabolic health or hydration. Practical habits to consider: choose protein supplements that fit dietary preferences and allergy status (nuts), pay attention to total daily protein distribution (e.g., adequate protein across meals), monitor gastrointestinal response when trying a new product, and prioritize whole-food sources of protein and fibre as part of an overall balanced diet. People with kidney disease or other medical conditions should consult a healthcare professional before adopting high-protein supplements. Future long-term trials are needed before making definitive recommendations.
Key Findings
- Almond protein and whey protein beverages produced comparable acute effects on appetite regulation, gastrointestinal symptoms and hydration in postmenopausal women.
- The trial was small (n=9) and assessed only single-dose acute responses in a crossover design, limiting generalisability; larger and longer studies are needed to corroborate these preliminary results.